The pathogenesis of type 2 diabetes includes pancreatic β-cell dysfunction and insulin resistance; most importantly in hepatocytes, myocytes, and adipocytes. Type 2 diabetes is well known to be a progressive disorder 1 characterized by deteriorating capacity for insulin release and action. Both defects are recognizable early on and present even in non-diabetic offspring of patients with type 2 diabetes.
Muscle
Impaired oxidative phosphorylation by muscle mitochondria is associated with insulin resistance. Nicotinamide adenine dinucleotide (NADH) oxidoreductase and citrate synthase activity were noted to be reduced in mitochondria isolated from human muscle biopsy specimens obtained from diabetic and obese subjects compared with lean subjects. 5 Mitochondrial oxidative phosphorylation has also been assessed in human muscle in vivo using nuclear magnetic resonance (NMR) spectroscopy. In this way, Szendroedi et al. 6 demonstrated defective muscle adenosine triphosphate (ATP) synthetic flux in subjects with type 2 diabetes, even under hyperinsulinemic, hyperglycemic conditions.
Studies using 13 C NMR to assess tricarboxylic acid (TCA) flux rates along with 31 P NMR to assess phosphorylation of adenosine diphosphate (ADP) demonstrated impaired skeletal muscle oxidative phosphorylation, increased intra-myocellular lipid, and decreased TCA cycle substrate oxidation in insulin-resistant offspring of individuals with type 2 diabetes. [7] [8] [9] Similar findings were reported in the muscle of elderly subjects with insulin resistance compared with young controls. 10 In another study, type 2 diabetes was characterized by increased lipid content in myocytes as well as a relative decrease in the proportion of enzymes regulating oxidative, as opposed to glycolytic, metabolism.
Furthermore, exercise tolerance and recovery of intracellular phosphocreatine post-exercise are impaired in subjects with type 2 diabetes consistent with mitochondrial dysfunction.
12,13
Other studies of mitochondria or saponin-permeabilized muscle fibers isolated from humans with type 2 diabetes showed impairments in oxygen consumption 14, 15 even when normalized for mitochondrial content. 15 However, another report showed that mitochondrial respiration was normal when expressed per DNA content, suggesting that the impairment was not in function but in number of mitochondria. 16 In a recent study of mitochondria isolated from insulin-resistant, obese, but not diabetic humans compared with insulin-sensitive lean subjects, maximal respiration rates were increased in the obese subjects 17 associated with increased H 2 O 2 production. That study also showed that the mitochondria of the insulin-resistant subjects maintained a higher extra-mitichondrial ATP free energy suggesting a higher thermodynamic driving force thought responsible for the increase in ROS production.
Perturbed mitochondrial biogenesis may be a cause of reduced mitochondrial number as well as reduced capacity for oxidative phosphorylation in diabetes. An important factor driving mitochondrial biogenesis at the molecular level is the peroxisome proliferator-activated receptor gamma (PPARγ) coactivator (PGC-1α), representing a coactivator of nuclear transcription factors, PPARγ and PPARα, and several other genes involved in energy homeostasis. [18] [19] [20] Muscle biopsy studies showed that PGC-1α is reduced in patients with type 2 diabetes 21-23 as well as in family members of individuals with type 2 diabetes.
23
There have been recent studies of intrinsic respiration by heart and skeletal muscle mitochondria isolated from tissues of type 2 diabetic models. Boudina et al. 24 examined heart mitochondrial function in saponin-permeabilized heart muscle fibers obtained from insulin-resistant, diabetic, leptin-receptor-deficient db/db mice. These investigators reported decreased respiration on complex I substrates and on palmitoyl-carnitine, associated with proportionally reduced ATP production and decreased content of the F1 alpha-subunit of ATP synthase. Our laboratory recently examined respiratory function in heart and skeletal muscle mitochondria isolated from high-fat-fed rats also subject to low-dose streptozotocin (STZ) to mimic impaired glucose tolerance. 25 Our data revealed no change in respiration in these mildly hyperglycemic rats compared with high-fat-fed controls.
High-fat feeding associated with insulin resistance 26 results in downregulation of several human genes involved in oxidative phosphorylation and mitochondrial biogenesis. 27 Metabolomic studies in rodents suggest that enhanced fat metabolism seen with high fat feeding overloads muscle mitochondria with oxidation products in a way that restricts their ability to completely metabolize these products to CO 2 . Koves et al. 28 showed that high-fat feeding increased acylcarnitines representing products of incomplete β-oxidation of fatty acids. This was associated with decreased TCA intermediates and an inability of mitochondria to switch from using fat-derived substrates to the glucose-derived metabolite, pyruvate. These perturbations could be prevented by restricting the mitochondrial entry of fatty acids by knock-out of malonyl coenzyme-A (malonyl-CoA) decarboxylase (MCD).
These data were interpreted to imply that the mitochondria of high-fat-fed rodents are exposed to increased, rather than decreased, rates of β-oxidation, but become impaired and unable to handle the high rate of flux.
How do the above findings translate to insulin resistance? As indicated in Figure 1 , there is a rationale whereby mitochondrial dysfunction (or reduced mitochondrial density) might impair insulin signaling. 
Liver
Any mitochondrial-mediated alteration in energy hemostasis in hepatocytes would impact the balance between gluconeogenesis, glycolysis, and glycogen storage/breakdown, thereby impacting glycemia in diabetic states. In hepatocytes, PGC-1α regulates gluconeogenesis and fat oxidation. 32 The NAD + -dependent histone deacetylase, SIRT1, increases gluconeogenesis in liver cells through its effects on PGC-1. 33 Consistent with the above, mice deficient in PGC-1 possibly a mechanism for improved whole body insulin sensitivity.
Islet β-cells
Beyond actions on insulin-sensitive target cells, mitochondria are critical in modulating β-cell insulin secretion. As depicted in Figure 2 , any alteration in mitochondrial function that could change ATP production would have a major impact on the capacity of glucose to trigger insulin secretion. In particular, altered activity of uncoupling protein 2 (UCP2), the UCP subtype expressed in islets, would be important given its effect of reducing ATP production at any given level of fuel oxidation. Indeed, Zhang et al. 44 reported that mice genetically deficient in UCP2 manifest higher islet ATP levels and increased glucose-stimulated insulin release.
Further, the defect in first-phase insulin release, known to be present in leptin-deficient obese ob/ob mice, could be restored by UCP2 knock-out. 44 UCP2 knockout also protected insulin release in high-fat-fed rodents and in islets exposed to lipid in vitro. 45, 46 Interestingly, a kinetic analysis 47 revealed that the ATP-ADP ratio was much more regulated by mitochondria in islet β-cells (modeled by insulinoma cells) than by mitochondria of skeletal muscle, underscoring the importance of mitochondria in regulating islet insulin secretion. As opposed to UCP knock-down, overexpression of UCP2 inhibits glucose-induced insulin release as demonstrated by our laboratory using INS-1 cells 48 and by
Chan et al. 49 in cultured pancreatic islets.
UCP2 may mediate a link between mitochondrial superoxide production and impaired insulin release, possibly explaining the progressive nature of type 2 diabetes. In this paradigm, islets exposed to high concentrations of glucose or fatty acids may generate more superoxide (see below). Superoxide is known to activate UCPs, possibly as a feedback means of protection from further radical generation through reduction of membrane potential. 50 However, this would also decrease ATP formation and reduce insulin secretion. In fact, Krauss et al. 51 showed that induction of UCP2 by endogenous superoxide-impaired insulin secretion from isolated islets in wildtype but not UCP2 knock-out mice.
In past years, glycolysis and glucokinase have been considered the major factors regulating glucose-induced insulin secretion. 52 However, the above considerations now direct attention to mitochondria with a major role for UCP2 in modulating mitochondrial potential, ATP Diabetes Pathophysiology production, and therefore insulin release. 53 The interrelations of mitochondrial ATP formation, mitochondrial uncoupling, and insulin release are depicted in Figure 2 .
Glucose-induced insulin release is dependent on mitochondrial adenosine triphosphate (ATP) generation and affected by both mitochondrial reactive oxygen species (ROS) and uncoupling protein-2 (UCP2
Interestingly, insulin resistance at the level of skeletal muscle may induce islet β-cell mitochondrial dysfunction and progression to diabetes. Evidence for this comes form the MKR mouse, which has a dominant-negative IGF-I receptor mutation specifically in skeletal muscle leading to insulin resistance and hyperglycemia. 54 
Mitochondrial Morphology, Fission, and Fusion
Beyond, mitochondrial function, type 2 diabetes is associated with changes in the size, number, and morphology of muscle mitochondria.
Biopsies of skeletal muscle from subjects with type 2 diabetes and obesity reveal lower density of mitochondria and smaller size; size correlating to whole body insulin sensitivity. 5, 75 There is also mitochondrial subtype selectivity in muscle. Skeletal myocytes and cardiomyocytes contain two populations of mitochondria: subsarcolemmal (SLM) and intermyofibrillar (IMFM). Electron microscopy revealed reduced numbers of SLM mitochondria in skeletal muscle of type 2 diabetic and obese subjects associated with reduced electron transport activity per unit mitochondrial DNA, suggesting functional impairment as well. 75 It is believed that the SLM contribute energy for membrane and transport processes while the IMFM contribute more to contractile function. Interestingly, type 2 diabetes is also associated with increased SLM lipid accumulation compared with obese controls. 76 Mitochondrial networking in the form of frequent fusion and fission events may play a role in regulating β-cell function and sensitivity to apoptosis. There is evidence that high nutrient exposure of islet β-cells in vitro leads to arrest of fusion activity and fragmentation. Shifting the dynamics to fusion by inhibiting fission seems to prevent β-cell apoptosis. 77 Fusion and fission depend on certain proteins including two isoforms of mitofusin, which are involved in docking, and the presenillin-associated rhomboid-like (PARL) protein, important for morphologic integrity. 78 There is now evidence that obesity in both humans and rodents is associated with reduced mitofusin (MFN). 79 Moreover, polymorphisms of PARL in humans are associated with insulin resistance.
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Mitochondrial Calcium and the Pathogenesis of Diabetes
A large volume of literature links calcium flux to mitochondrial function.
Ionic calcium influx increases respiration and ATP formation, probably
by enhancing the activity of mitochondrial dehydrogenase enzymes and stimulation of ATP synthase. 81 However, whether alterations in calcium handling are of primary importance in the pathology associated with diabetes is not clear. Oliveira et al. 82 reported that heart mitochondria isolated from 21-day STZ-diabetic rats with severe hyperglycemia demonstrated increased sensitivity to calcium-triggered reduction in
membrane potential. Prevention of this by cyclosporin suggested that this was due to greater susceptibility of these mitochondria to opening of the mitochondrial permeability transition pore. 82 There is evidence for leakage of calcium from muscle sarcoplasmic reticulum stores in db/db mice 83 and impaired mitochondrial calcium transients in ob/ob mice.
84,85
In islet β-cells, calcium is a critical mediator for respiration and consequent ATP formation and for insulin release by a direct effect on extrusion of the stored hormone from intracellular granules. As noted above, impaired calcium signaling has been noted in islets of hyperglycemic insulin-resistant MKR mice.
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Mitochondria of Multiple Cell Types and Type 2 Diabetes
Given the above considerations, we can ask how mitochondrial dysfunction within different cell and tissue types might lead to type 2 diabetes or, if not directly causative, how mitochondrial dysfunction could contribute to the progressive nature of diabetes and its complications. Figure 3 represents a simplistic and hypothetical overview of this process. Obviously, there is considerable detail to be resolved. Hopefully, further understanding will lead to approaches that effectively target mitochondria within multiple tissues in a way that mitigates the pathophysiology involved in the onset and progression of type 2 diabetes.
Therapeutic Considerations
Based on the above, therapy directed at mitochondria could prove an effective way to prevent, treat and/or to minimize the complications of diabetes (see Figure 4) . Exercise increases mitochondrial biogenesis through effects on PGC-1 86, 87 and activates adenosine monophosphate (AMP)-activated protein kinase (AMPK), which improves both glucose and fat oxidation. 86 A recent study revealed that aerobic exercise training increased insulin sensitivity, maximal oxygen consumption, and mitochondrial respiration in both type 2 diabetic subjects and obese controls matched for age and body mass index (BMI). 88 However, there was no difference in these parameters between these groups. Calorie restriction favors mitochondrial biogenesis, oxygen use, ATP formation, and expression of SIRT1, which activates PGC1-α. 89, 90 There is also evidence that n-3 polyunsaturated fatty acids activate AMPK, favoring mitochondrial biogenesis and enhance lipid catabolism in adipose tissue and liver, suppressing lipogenesis. PGC-1α and genes in the fatty acid oxidation pathway. 43 However, somewhat paradoxically, thiazolidinediones are limited by a tendency for weight gain due to increased fat, 93 fluid retention, and heart failure. 94 Metformin, most often used in the initial pharmacologic management of type 2 diabetes, has mitigating effects on ROS production, activates AMPK, and favors mitochondrial proliferation. 95, 96 In addition, there is evidence that angiotensin receptor blockers or inhibitors of angiotensin-converting enzyme enhance mitochondrial biogenesis. 97 Newer approaches may soon be available. Resveratrol, an ingredient in red wines, is a polyphenolic SIRT1 activator which, at least in rodents, improves insulin resistance, protects against diet-induced obesity, Diabetes Pathophysiology induces genes for oxidative phosphorylation, and activates PGC-1α. [98] [99] [100] Recently, it has been reported that the adipokine apelin enhances mitochondrial content in muscle by means independent of AMPK and PGC-1α. 101 It may also be possible to improve glucose utilization through measures that inhibit mitochondrial uptake of long-chain acyl-CoA 109 Of note is that ubiquinol, the reduced from of CoQ, does not directly scavenge oxygen radicals but acts as an antioxidant in mitochondria both by regeneration of vitamin E and by reacting with peroxyl radicals, serving as a chain-breaking agent towards lipid peroxidation. 110 In fact, we and others 111, 112 have shown that mitochondrial-targeted coenzyme Q (mitoQ) actually increases superoxide production when added directly to isolated mitochondria, an effect that is mediated by the semiquinone form of mitoQ generated during redox cycling of the compound.
MitoQ also has metabolic effects when added to mitochondria, including uncoupling properties, so one can speculate that mitochondrial-targeted agents like coenzyme Q might be potentially useful in treating obesity. 113 Other 
